Climb Bio, Inc. (CLYM) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−12.0x

Market Cap

$891.41M

MomentumView details →

1D Return

+6.37%

YTD Return

+289.17%

RSI (14)

53.8

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−12.0x

Market Cap

$891.41M

RSI (14)

53.8

MomentumView details →

1D Return

+6.37%

YTD Return

+289.17%

SummaryUpdated Jun 1, 2026

Climb Bio, Inc. (NASDAQ:CLYM) is a clinical-stage biotechnology company founded in 2018 and headquartered in Wilmington, Delaware. The company was originally incorporated as Eliem Therapeutics, Inc. before changing its name to Climb Bio in October 2024. Climb Bio focuses on developing innovative therapies for autoimmune-driven inflammatory diseases, with its lead drug candidate budoprutug currently in clinical development for multiple autoimmune conditions including systemic lupus erythematosus and lupus nephritis.

Ask drillr about Climb Bio, Inc. →

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−24.06%

ROA (TTM)

−23.40%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

−18.57%

FCF YoY

−33.55%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+42.48%

EBITDA YoY

−14.03%

EarningsView details →

EPS (Actual)

−$0.18

EPS Surprise

14.00%

Beats (12Q)

3/12

Next Q EPS Est

−$0.20

Avg Surprise (4Q)

−3.36%

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

31.45x

Quick Ratio

31.45x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−57.62M

Op. CF (TTM)

−52.70M

Next earningsNov 11, 2026 →

Latest newsMore news →

Climb Bio Inc. released preliminary data from its ongoing Phase 1 trial of CLYM116 for IgA nephropathy and announced updated strategic plans for the treatment.1d ago

Climb Bio, Inc. reported a net loss of $13.5 million for Q2 2026, compared to a net loss of $8.7 million in Q2 2025.30d ago

Similar companies

Cybin Inc. Common StockHELP Theravance Biopharma, Inc.TBPH Silence Therapeutics plcSLN Rigel Pharmaceuticals, Inc.RIGL Achieve Life Sciences, Inc.ACHV CANbridge Pharmaceuticals Inc.01228.HK Find similar companies →

Latest newsMore news →

Climb Bio Inc. released preliminary data from its ongoing Phase 1 trial of CLYM116 for IgA nephropathy and announced updated strategic plans for the treatment.1d ago Climb Bio, Inc. reported a net loss of $13.5 million for Q2 2026, compared to a net loss of $8.7 million in Q2 2025.30d ago